Streetbeat News

Price Targets

IAC

Citigroup analyst Ygal Arounian has maintained a 'Buy' rating on IAC (NASDAQ:IAC) but lowered the price target from $71 to $69.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:57 am

SIRI

Rosenblatt analyst Barton Crockett maintains a neutral stance on Sirius XM Holdings (NASDAQ:SIRI), raising the price target from $4.1 to $5.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 11:57 am

TTD

Citigroup analyst Ygal Arounian maintains a Buy rating on Trade Desk (NASDAQ:TTD) and raises the price target from $86 to $96.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:56 am

MGNX

HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Macrogenics (NASDAQ:MGNX) and maintained a $14 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 11:56 am

ARHS

DBTX

DCPH

FLT

GPN

IIIV

NVEI

OSPN

TERN

VRDN

WIX

Several analyst forecasts were released on Thursday, with price target changes for i3 Verticals, Arhaus, Wix.com, FLEETCOR Technologies, Viridian Therapeutics, Terns Pharmaceuticals, Deciphera Pharmaceuticals, Global Payments, OneSpan, Nuvei Corporation, and Decibel Therapeutics. The changes included both upgrades and downgrades, with the most significant being a price target cut for Decibel Therapeutics from $21 to $5.25 by Baird.

Portfolio Pulse from Lisa Levin

August 10, 2023 | 11:53 am

IPSC

HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Century Therapeutics (NASDAQ:IPSC) but lowers the price target from $17 to $13.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 11:52 am

GRTS

HC Wainwright & Co. analyst Sean Lee has reiterated a 'Buy' rating on Gritstone Bio (NASDAQ:GRTS) and maintained a $7 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 11:51 am

PENN

Barclays analyst Brandt Montour has maintained an Overweight rating on PENN Entertainment (NASDAQ:PENN) and raised the price target from $33 to $36.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:51 am

CDXC

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on ChromaDex (NASDAQ:CDXC) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 11:50 am

DCPH

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Deciphera Pharmaceuticals (NASDAQ:DCPH) and maintained a price target of $25.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 11:49 am